文献速递胸部技术与安全CT

低中等收入地区局部晚期非小细胞肺癌放疗中适应性剂量递增的潜力

Potential for adaptive dose escalation in radiotherapy for patients with locally advanced non-small-cell lung cancer in a low mid income setting.
PubMed 文献 · Br J Radiol · 2017-01-03

研究对20例接受根治性放化疗的局部晚期非小细胞肺癌患者,在第5周(45 Gy)行CT评估肿瘤体积退缩并重新计划。同步放化疗组肿瘤退缩高于序贯组(p=0.02)。10例退缩>20%者重新计划后靶区覆盖指数改善、危及器官剂量降低,其中4例(40%)可实现剂量递增。

要点

  • 同步放化疗组肿瘤退缩较序贯组更明显(p=0.02)。
  • 45 Gy时肿瘤体积退缩约35%,重新计划可改善适形度并降低危及器官剂量。
  • 40%患者可在45 Gy单次诊断扫描基础上实现剂量递增。

核心结论

  • 放化疗至45 Gy时肿瘤体积退缩约35%,可改善适形度、降低危及器官剂量,并使40%患者实现剂量递增。

研究设计与样本

  • 研究纳入20例接受根治性放化疗的局部晚期非小细胞肺癌患者,在放疗第5周行CT_45扫描评估肿瘤体积退缩。
  • 对退缩>20%的10例患者进行重新计划,评估靶区覆盖指数和危及器官剂量变化,并探索在危及器官耐受范围内最大剂量递增的可行性。

诊断标准与关键数值

  • 同步放化疗组肿瘤退缩高于序贯放化疗组(p=0.02)。
  • 适应性计划后平均覆盖指数从0.96(±0.14)升至1.29(±0.36),平均外体积指数从1.39(±0.60)变为1.41(±0.56)。
  • 危及器官剂量降低:全肺平均肺剂量(MLDWL)降低10.6%,全肺V20WL降低1.3%,全肺V5WL降低1.2%,患侧肺MLDIL降低6.6%,患侧肺V20IL降低1.5%,患侧肺V5IL降低2.3%。
  • 食管平均剂量降低7%,食管V50降低31%,脊髓最大剂量降低0.35%。
  • CT_45时4例患者可实现剂量递增。

临床应用与阅片要点

  • 在资源有限地区,45 Gy时单次诊断扫描行适应性计划可能有助于改善放疗计划指标并在尊重危及器官剂量前提下实现剂量递增。
  • 该简单策略在40%的局部晚期非小细胞肺癌患者中有助于直至60 Gy的放疗计划。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To evaluate the effect of tumour volume regression on adaptive treatment planning, reduction in doses to organs at risk (OARs) and dose escalation.

METHODS: 20 patients undergoing radical chemoradiotherapy were imaged in the fifth week of radiotherapy (CT_45) to evaluate differences in tumour volume regression between concurrent and sequential chemoradiotherapy. Replanning was carried out in the CT_45 in those with >20% regression (n = 10) and evaluated for change in target coverage indices (the coverage index and external volume index) and doses to the OAR [mean lung dose, V20 and V5 of whole and ipsilateral lung (MLDWL, V20WL, V5WL, MLDIL, V20IL, V5IL); mean oesophagus dose, V50oesophagus; and maximum spinal cord doses]. The feasibility of maximum dose escalation was explored keeping the limit of the OAR below their tolerance limits.

RESULTS: Tumour regression was higher with concurrent chemoradiotherapy as compared with sequential chemoradiotherapy (p = 0.02). With the adaptive plan, the mean coverage index improved from 0.96 (±0.14) to 1.29 (±0.36), the mean external volume index changed from 1.39(±0.60) to 1.41(±0.56) and the reduction in doses to the OARs were MLDWL 10.6%, V20WL 1.3%, V5WL 1.2%, MLDIL 6.6%, V20IL 1.5%, V5IL 2.3%, mean oesophagus dose 7%, V50oesophagus 31% and maximum cord dose 0.35%. Dose escalation was possible in four patients in CT_45.

CONCLUSION: There is 35% reduction in tumour volume with chemoradiotherapy at 45 Gy which allows improvement in conformality, reduction in doses to the OARs and dose escalation in 40% of patients. Advances in knowledge: This article emphasizes that adaptive planning with a single diagnostic scan at 45 Gy has the potential for improvement of radiotherapy planning indices, dose escalation while respecting the dose to the OAR. This simple strategy can be helpful in radiotherapy planning upto 60 Gy in 40% of the patients of locally advanced non-small-cell lung cancer in countries with limited resources.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Agrawal S, Kumar S, Maurya AK, et al. Potential for adaptive dose escalation in radiotherapy for patients with locally advanced non-small-cell lung cancer in a low mid income setting. Br J Radiol. 2017. PMID: 27897060. doi:10.1259/bjr.20140234

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。